BioVisionAI is a pioneering company dedicated to transforming pathology through artificial intelligence. They develop cutting-edge AI software designed to assist pathologists in detecting and diagnosing cancer with greater speed, accuracy, and efficiency. BioVisionAI's solutions aim to streamline diagnostic workflows, reduce the potential for human error, and ultimately improve patient care by leveraging sophisticated deep learning algorithms trained on extensive datasets of histopathological images. Their focus is on creating tools that empower medical professionals and contribute to better outcomes in oncology.
The Pleasanton headquarters serves as BioVisionAI's central hub for research and development, software engineering, artificial intelligence model training, clinical validation, business operations, and strategic leadership.
While specific architectural details are not widely publicized, the facility is expected to house advanced computing infrastructure for AI development, data analysis laboratories, and collaborative workspaces designed for a high-tech R&D company.
The work culture at BioVisionAI's headquarters is likely innovative, collaborative, and mission-driven, focusing on cutting-edge AI research in a fast-paced startup environment. Emphasis is placed on scientific rigor, technological excellence, and a shared goal of transforming cancer diagnostics to improve patient outcomes. It likely fosters a learning environment with opportunities for growth and significant impact.
Its location in the San Francisco Bay Area provides BioVisionAI with strategic access to a rich talent pool in AI, software development, and life sciences, as well as proximity to venture capital, research institutions, and potential industry partners.
While headquartered in the United States, BioVisionAI aims to make a global impact on cancer diagnostics. Their AI-powered software solutions are designed for deployment in pathology laboratories and healthcare institutions worldwide. BioVisionAI's global presence is primarily facilitated through the international reach of its technology, strategic partnerships with healthcare providers and distributors in various regions, and collaborations with international research organizations, rather than an extensive network of physical international offices.
4847 Hopyard Rd, Suite H-10
Pleasanton
CA
USA
Address: N/A
N/A - Operations are centralized at the main headquarters.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BioVisionAI' leadership includes:
BioVisionAI has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major C-suite level executive hires or departures publicly announced for BioVisionAI within the last 12 months (as of mid-2024). The founding executive team and key leadership appear to be stable. The most recent significant leadership additions, such as the VP of Product Management and CMO, joined in early 2023.
Discover the tools BioVisionAI uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BioVisionAI likely utilizes common professional email formats for its employees. Based on industry patterns and data observed for some personnel, primary formats could include [first name]@[companydomain].com or [first initial][last name]@[companydomain].com. The domain used is biovisionai.com.
[first]@biovisionai.com or [f][last]@biovisionai.com
Format
example: titash@biovisionai.com or tnag@biovisionai.com
Example
70%
Success rate
PR Newswire • December 7, 2023
BioVisionAI announced that its AI software for detecting gastric cancer and dysplasia has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation is intended to expedite the development and review of medical devices that offer potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases....more
Business Wire • July 11, 2023
BioVisionAI successfully closed a $5.2 million seed funding round. The round was led by Fusion Fund, with participation from existing investors Artiman Ventures and GRIDS Capital, as well as new investor Amino Capital. The capital is aimed at accelerating product development, expanding the team, and pursuing FDA clearance for its AI pathology solutions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BioVisionAI, are just a search away.